1.25
+0.19(+17.92%)
Currency In USD
| Previous Close | 1.06 |
| Open | 1.25 |
| Day High | 1.43 |
| Day Low | 1.04 |
| 52-Week High | 5.1 |
| 52-Week Low | 0.36 |
| Volume | 95.79M |
| Average Volume | 8.61M |
| Market Cap | 149.52M |
| PE | -0.64 |
| EPS | -1.95 |
| Moving Average 50 Days | 0.53 |
| Moving Average 200 Days | 1.14 |
| Change | 0.19 |
If you invested $1000 in Invivyd, Inc. (IVVD) since IPO date, it would be worth $59.87 as of February 05, 2025 at a share price of $1.25. Whereas If you bought $1000 worth of Invivyd, Inc. (IVVD) shares 3 years ago, it would be worth $135.14 as of February 05, 2025 at a share price of $1.25.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Invivyd Announces Positive Phase 1/2 Clinical Data for VYD2311, a Monoclonal Antibody Designed to be a Superior Alternative to COVID-19 Vaccination for the Broad Population
GlobeNewswire Inc.
Feb 03, 2025 12:00 PM GMT
Recruitment completed and all doses administered for VYD2311 ongoing Phase 1/2 clinical trial (40 subjects) evaluating 3 routes of administrationPhase 1/2 clinical data for VYD2311 to date are positive for both safety and pharmacokinetics, and are su
Invivyd Announces Preliminary Fourth Quarter 2024 Financial Results, Strong Revenue Growth, and Reiterates Goal of Near-Term Profitability
GlobeNewswire Inc.
Feb 03, 2025 11:55 AM GMT
Preliminary Q4 2024 PEMGARDA™ (pemivibart) net product revenue of $13.8 million, 48% growth over Q3 2024 net product revenue of $9.3 millionPreliminary Q4 2024 total operating costs and expenses of approximately $32 million, 55% reduction compared to
Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA’s Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients
GlobeNewswire Inc.
Jan 27, 2025 12:01 PM GMT
Treatment immunobridging analysis, routinely updated for contemporary SARS-CoV-2 variants, compares pemivibart antiviral titers to adintrevimab antiviral titers from the company’s previous Phase 2/3 clinical trial of adintrevimab for the treatment of